Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy…

Continue Reading

News Source: medicalxpress.com